In order to compare the iron concentrations of the marketed ferruginous hematinics with the sustained-releasedosage forms and to prepare the good hemantinic which can be absorbed effectively without forming "iron block" in the gastrointestinal tract, gelatinized micropellets containing medicament were prepared and hardened in 10% formalin-isopropanol in the time of 72 hours. These micropellets were digested with artificial gastric juice and plotted a curve of released iron concentration. As a result, it is found that gelatinized micropellets sustained-release dosage form is an excellent ferruginous hemantinic and it is shown that several marketed preparations can be improved in their hemantinic actions by forming the sustained-release dosage.se dosage.

Nine novel compounds, namely, 2-(p-aminobenzenesulfonamideo)-6-sulfamylbenzothiozle, 2-benzamido-6-sulfamylbenzothiazole, 2-(p-toluenesulfonamide)-6-sulfamylbenzothiazole, 2-(3,5-dinitrobenzamido)-6-sulfamylbenzothiazole, 2-benzamido-6-nitrobenzothiazole, 2-(p-toluene-sulfonamido)-6-nitrobenzothiazole, 2-(3,5-dinitrobenzamido)-6-nitrobenzothiazole, 2-(p-toluenesulfonamido)-6-chlorobenzothiazole, 2-(3,5-dinitrobenzamido)-6-chlorobenzothiazole were synthesized and evaluated for their in vitro antimicrobial activity against Staphylococcus aureus wood 46, $\betha$-Streptococcus S86, Escherichia coli and antitubercular activity against Mycobacterium tuberculosis H$_{37}$ /Rv. 2-(p-Toluenesulfonamido)-6-chlorobenzothiazole showed antimicrobial activity at 25 $\mu$g/ml against $\betha$-Streptococcus S/86, 2-(3,5-Dinitrobenzamido)-6-sulfamylbenzothiazole was active at 5 $\mu$g/ml and 2-(3,5-dinitrobenzamido)-6-nitrobenzothiazole was consderably active at 1$\mu$g/ml against Mycobacterium tuberculosis H$_{37}$Rv.

Fourteen novel N,N'-disubstitued thiourea derivatives were synthesized by Hugershof reaction. Antitubercular activities of ten compounds against Mycobacterium tuberculosis H$_{37}$ Rv were tested and was found tat 1-cyclohexyl-3-(4-benzenesulfonepiperidide)-2-thiourea was considerably active at 1mg/ml and 1-$\alpha$-naphthyl-3-(4-benzenesulfonepiperidide)-2-thiourea was slightly active at 1mg/ml. Antibacterial activity of the newly synthesized compounds against E. coli, Sta. aureus and Streptococcus hemolyticus were also tested. 1-cyclohexyl-3-(4-benzenesulfonepiperidide)-2-thiourea was makedly active against E. coli, Sta, aureus and Streptococcus hemolyticus; Phenol coefficients against E. coli, Sta, aureus and Streptococcus hemolyticus were 30,17.5 and 21.3, respectively. 1,1'-p-phenylene-3,3'bis[N-(2-thiazolyl)-sulfamylphenyl]-2,2'-dithiourea and 1-$\alpha$-naphthyl-3-(4-benzenesulfonepiperidide)-2-thiourea were considerably active against E. coli: phenol coefficients, 18.8 and 37.5 respectively. 1-(4-ethoxyphenyl)3-(4-sulfamylphenyl)-2-thiourea was active against Streptococcus hemolyticus: phenol coefficients, 22.5. 1-$\alpha$-naphthyl-3-(4-sulfamylphenyl)-2-thiourea, 1-$\betha$-naphthyl-3-[4-N-(2-thiazolyl)-sulfamylphenyl]-2-thiourea and 1-$\alpha$-naphthyl-3-(4-benzenesulfonepiperidide)-2-thiourea were active against Sta. aureus: phenol coefficients, 17.5, 20.0 and 18.8 respectively.

Seventeen novel compounds of thiosemicarbazone derivatives were synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H$_{37}$Rv and antibacterial activity against Staphylococcus aureus, Escherichia coli. It was found that 4-($\alpha$-naphthyl)-1-(2-furfuraldehyde)-3-thiosemicarbazone was active at 0.01$\mu$g/ml and 1, 1'-(p-phenylene)-4, 4'-bis(phenyl)-2, 2'-dithiosemicarbazide, at 0.01$\mu$g/ml against E. coli, respectively.

상륙(Phytolacca esculenta)에서 새로운 물질 trihydroxyolean-12-ene dicarboxylic acid, $C_{30}H_{46}O_{7}$, m.p.318-$320^{\circ}$, [$\alpha$]$_D$$^{6}$ = +113.$7^{\circ}$를 분리하고 jaligonic acid라고 명명하였다. 본물질은 carrageenin으로 유발시킨 edema형성을 강력하게 억제하였다.